Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telmisartan/hydrochlorothiazide - Boehringer Ingelheim

Next Previous
X
Search
Drug Profile

Telmisartan/hydrochlorothiazide - Boehringer Ingelheim

Alternative Names: BIBR 277HCT; Kinzalkomb; Micardis Plus; MicardisPlus 80/25; Micombi; Pritor Plus

Latest Information Update: 08 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Astellas Pharma; Bayer; Boehringer Ingelheim Pharma KG
  • Class Antihypertensives; Benzimidazoles; Benzoates; Benzothiadiazines; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 08 Mar 2022 Discontinued - Phase-III for Hypertension (Combination therapy) in Japan (PO)
  • 30 Oct 2020 Astellas Pharma terminates its sales agreement for the Micardis family, prior to October 2020
  • 30 Jan 2020 No development reported - Phase-III for Hypertension (Combination therapy) in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top